癌症研究
基因沉默
转移
肝细胞癌
下调和上调
糖酵解
瓦博格效应
细胞生长
癌变
细胞培养
癌症
癌细胞
生物
医学
内科学
新陈代谢
生物化学
基因
遗传学
作者
Juan Yang,Cun Wang,Fengbo Zhao,Xiaoying Luo,Meilin Qin,Einthavy Arunachalam,Zhouhong Ge,Ning Wang,Xuan Deng,Guang‐Zhi Jin,Wen‐Ming Cong,Wenxin Qin
出处
期刊:Carcinogenesis
[Oxford University Press]
日期:2016-10-14
卷期号:: bgw109-bgw109
被引量:44
标识
DOI:10.1093/carcin/bgw109
摘要
Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI